IP Library Granted Patent US 9,382,422
Granted Patent B2
US 9,382,422 · App. 12/747,441 · Granted Jul 5, 2016

Acellular tissue matrix compositions for tissue repair

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,382,422
App. No.
12/747,441
Granted
Jul 5, 2016
Kind
B2
Abstract

The invention provides tissue repair compositions and methods of making the tissue repair compositions. Also featured are methods of treatment using the tissue repair compositions and articles of manufacture that include the tissue repair compositions.

Claims (44)

1. A method of making a biocompatible mesh composition, the method comprising:

a) selecting a tissue;

b) preparing an acellular tissue matrix (ATM) by treating the tissue to remove cellular material from the tissue, wherein the ATM retains biological functions which are provided by undenatured collagenous proteins and non-collagenous molecules;

c) processing the ATM to produce a plurality of particles, of intact ATM;

d) incubating the plurality of particles of intact ATM in an acidic solution to create a suspension of swollen ATM particles of intact ATM, wherein the acidic solution has a pH from about 1.0 to about 3.0; and

e) applying the suspension to a biocompatible mesh substrate composition and drying the composition to create a coated mesh substrate.

2. The method of claim 1 , wherein steps (d) and (e) are performed simultaneously.

3. The method of claim 1 , wherein the tissue is dermis.

4. The method of claim 1 , wherein the tissue is selected from the group consisting of fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

5. The method of claim 1 , wherein the tissue is human tissue.

6. The method of claim 1 , wherein the tissue is made from non-human mammalian tissue.

7. The method of claim 6 , wherein the non-human mammalian tissue is obtained from a pig.

8. The method of claim 6 , wherein the tissue is obtained from a non-human mammal that is genetically engineered to lack expression of α-1,3-galactosyl epitopes.

9. The method of claim 8 , wherein the non-human mammal lacks a functional α-1,3-galactosyltransferase gene.

10. The method of claim 1 , wherein the pH is from about 1.5 to about 2.5.

11. The method of claim 1 , wherein the pH is about 1.4.

12. The method of claim 1 , wherein the acidic solution is a solution comprising an acid selected from the group consisting of acetic acid, ascorbic acid, boric acid, carbonic acid, citric acid, hydrochloric acid, lactic acid, tannic acid, phosphoric acid, and sulfuric acid.

13. The method of claim 1 , wherein the acidic solution comprises 0.1 M acetic acid.

14. The method of claim 1 , wherein the acidic solution comprises 0.04 M hydrochloric acid.

15. The method of claim 1 , wherein the incubation step is for a period from about 0.5 hours to about 12 hours.

16. The method of claim 1 , wherein the incubation step is for a period from about 1.0 to about 10.0 hours.

17. The method of claim 1 , wherein the incubation step is for a period from about 2.0 to about 6.0 hours.

18. The method of claim 1 , wherein the incubation step is for a period from about 2.5 to about 5.0 hours.

19. The method of claim 1 , wherein the incubation step is for a period of about 3.0 hours.

20. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 20° C. to about 42° C.

21. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 20° C. to about 30° C.

22. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 25° C. to about 35° C.

23. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 30° C. to about 40° C.

24. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 35° C. to about 38° C.

25. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 37° C. to about 42° C.

26. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 37° C.

27. The method of claim 1 , wherein the incubating step, the drying step, or the incubating and the drying steps are at a temperature of about 25° C.

28. The method of claim 1 , wherein the biocompatible mesh substrate is non-absorbable.

29. The method of claim 1 , wherein the biocompatible mesh substrate is absorbable.

30. The method of claim 29 , wherein the biocompatible mesh substrate is a polymer.

31. The method of claim 30 , wherein the polymer comprises poly-4-hydroxybutyrate.

32. The method of claim 29 , wherein the absorbable biocompatible mesh substrate is a polymer selected from the group consisting of polyhydroxyalkanoate, polyglycolic acid, poly-l-lactic acid, polylactic/polyglycolic acid (PLGA), polygalactin 910, and carboxymethyl cellulose.

33. The method of claim 1 , wherein the biocompatible mesh substrate is a synthetic substrate.

34. The method of claim 33 , wherein the synthetic substrate comprises polypropylene.

35. The method of claim 1 , wherein the drying step comprises drying in a nitrogen atmosphere.

36. The method of claim 1 , wherein the drying step comprises freeze-drying.

37. The method of claim 1 , wherein treating the tissue to remove cellular material from the tissue includes removal of all cellular material.

38. The method of claim 1 , wherein the pH is from about 2.0 to about 3.0.

39. A biocompatible mesh composition made by the method of claim 1 .

Assignments (9)
RELEASE OF SECURITY INTEREST 037845/0497 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0603 →
RELEASE OF SECURITY INTEREST 040098/0268 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0554 →
RELEASE OF SECURITY INTEREST 040291/0237 Recorded Feb 2, 2017
From: WILMINGTON TRUST
To: LIFECELL CORPORATION
Reel/Frame 041608/0702 →
RELEASE OF SECURITY INTEREST Recorded Feb 1, 2017
From: BANK OF AMERICA, N.A.
To: LIFECELL CORPORATION
Reel/Frame 041143/0361 →
LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Oct 7, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040291/0237 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 21, 2016
From: KCI USA, INC.; LIFECELL CORPORATION; KCI LICENSING, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 040098/0268 →
RELEASE OF SECURITY INTEREST Recorded Sep 21, 2016
From: WILMINGTON TRUST
To: KCI LICENSING, INC.; LIFECELL CORPORATION; KINETIC CONCEPTS, INC.; TECHNIMOTION, LLC
Reel/Frame 040098/0200 →
SECURITY INTEREST Recorded Feb 17, 2016
From: KINETIC CONCEPTS, INC.; KCI USA, INC.; ACELITY L.P. INC.; CHIRON HOLDINGS, INC.; CHIRON TOPCO, INC.; KCI ANIMAL HEALTH, LLC; KCI HOLDING COMPANY, INC.; KCI HOMECARE, INC.; KCI IMPORTS, INC.; KCI INTERNATIONAL, INC.; KCI LICENSING, INC.; KCI PROPERTIES LIMITED; KCI REAL HOLDINGS, L.L.C.; KCI REAL PROPERTY LIMITED; KCI USA REAL HOLDINGS, L.L.C.; LIFECELL CORPORATION; TECHNIMOTION, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 037845/0497 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 10, 2015
From: OWENS, RICK T.; SUN, WENDELL
To: LIFECELL CORPORATION
Reel/Frame 037256/0522 →